Human immunodeficiency virus (HIV) infection is most often detected in the laboratory by demonstrating the presence of HIV-specific antibody. Test algorithms commonly used rely on an enzyme immunoassay (EIA) screen whereby specimens are classified as being either negative or repeatedly reactive. The antibody status of EIA repeatedly reactive serum samples should be verified by a supplemental assay, which frequently is the immunoblot. The sensitivity and specificity of viral lysate-based commercial EIA kits have been well documented (6, 9) .
The number of repeatedly reactive EIA serum samples that can be verified by immunoblot correlates with the prevalence of HIV infection in the population being studied (5, 13) . In low-prevalence populations, the majority of EIA reactive serum samples will test as immunoblot negative (3 Confirmatory tests. In-house Western blots were performed by using whole viral lysate (Organon Teknika, Scarborough, Ontario) as previously described (11) . In addition, the human T-cell lymphotropic virus type III By combining these data and those from Table 1 and by using the formulas of Ransohoff and Feinstein (8) , the sensitivity and specificity of the CBC Recombigen EIA were found to be 99.9 and 99.7%, respectively. The positive predictive value and negative predictive value of the test were 99.7 and 99.9%, respectively.
DISCUSSION
The screening test of choice in many laboratories for the detection of antibodies to HIV is the EIA, which employs disrupted whole viral lysate as its diagnostic antigen. This relatively inexpensive test has evolved into a highly sensitive and specific assay which can usually be completed in under 4 h.
The predictive values of an EIA are dependent not only on the sensitivity and specificity of the assay but also on the prevalence of disease in the test population. In general, as prevalence of infection increases, so does the positive predictive value (13) . At the same time, the negative predictive value declines. The opposite is true in populations at low risk for HIV infection.
As the uses for HIV testing have expanded to include insurance, employment, and visa screening, laboratories find that many individuals whose serum samples are repeatedly reactive in the EIA may be indeterminate in the Western blot. Except in some cases, such as seroconversion or passive antibody transfer (through hepatitis B immunoglobulin administration, for example), subsequent HIV testing on these individuals may not resolve their immune status (4) .
The CBC EIA was introduced into the FCA testing algorithm as a primary supplemental test to determine if, by this strategy, the number of indeterminate Western blot samples could be substantially reduced. To be of value, therefore, the test had to be at least as sensitive as currently available whole viral lysate ETAs and demonstrate higher specificity. The Western blot would still be considered the 4"gold standard," and HIV positivity would still require confirmation by the immunoblot procedure.
In this evaluation of 2,212 serum or plasma samples, the CBC Recombigen HIV EIA had a sensitivity of 99.9 and a specificity of 99.7%. In an earlier study in which a test utilized only recombinant envelope protein as the capture antigen, a sensitivity of 99.9 and specificity of 99.1% were obtained when 2,707 consecutive serum samples were tested (1) .
One potentially false-negative serum sample by the Recombigen test was received from the Haitian Red Cross, and a follow-up sample was unavailable. More diverse strains of HIV may be circulating in the Haitian population than in North America since the widely divergent HTLV RF strain was originally isolated from a Haitian (12) . Thus, a highly specific recombinant protein-based commercial kit designed for screening of North American sera may fail to detect antibodies elicited by HIV variants. Alternatively, the sample may have been cross-contaminated by another serum sample positive for HIV antibody. Data from CDC proficiency panels and in-house experience with diluted samples indicate that the CBC product does not detect diluted samples as efficiently as do viral lysate tests. Of the three CBC EIA potentially false-positive serum samples, two were from the Haitian Red Cross and follow-up testing could not be done. It is possible that these two specimens from a country with an HIV prevalence rate of 3 to 9% (7) may represent two early seroconversions. The Laboratory Services Branch, Ministry of Health, Toronto, Ontario, has reported that in some cases the CBC EIA kit was able to detect HIV antibody earlier than whole viral lysate EIA (C. Major, personal communication). In most of these cases, however, the immunoblots were indeterminate. The other CBC reactive sample was from an asymptomatic male who was not in any known risk group and may represent a true false-positive in the CBC EIA.
Over 19% of the total samples tested were indeterminate in Western blots. The band patterns observed with these specimens typically consisted of a 17,000 MW band (17K) only, a 24K band only, or 17K and 24K bands. Most ofthese specimens were received from Provincial Health Laboratories with HIV positivity rates ranging from 3 to 4%. Many of these specimens were CBC EIA negative and were confirmed negative by the supplemental tests.
If the EIA screen and Western blot use similar viral lysates, then EIA falsely reactive sera may not be resolved by Western blot since any nonspecific reactivity would be against the same nonviral proteins. There was no clinical or laboratory evidence which suggested that serum samples which were immunoblot indeterminate and CBC negative were from individuals infected with HIV.
The samples tested by the FCA represent a population for which the prevalence of HIV infection is high (52.9%), as 
